Printer Friendly

Insmed Added To Russell 3000 and Russell 2000 Indexes.

Business Editors/Health & Medical Writers

RICHMOND, Va.--(BUSINESS WIRE)--July 10, 2001

Insmed Incorporated (NASDAQ: INSM) today announced that it has been added to the Russell 3000(R) and Russell 2000(R) indexes.

The Russell 3000 Index measures the performance of the 3,000 largest U.S. companies based on total market capitalization, which represents approximately 98 percent of the investable U.S. equity market. The Russell 2000 Index measures the performance of the 2,000 smallest companies in the Russell 3000 Index.

"Insmed's addition to the Russell indexes is an important milestone," said Geoffrey Allan, Ph.D., president and chief executive officer of Insmed. "The listing increases our visibility among investors and validates that our product candidates address large, unmet medical needs in the treatment of diabetes and other disorders associated with insulin resistance."

About Insmed Incorporated

Insmed Incorporated is a biopharmaceutical company focused on the discovery and development of pharmaceutical products for the treatment of diabetes and other conditions associated with insulin resistance. Further information is available at

Statements included within this press release, which are not historical in nature, may constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements regarding expected financial position, results of operations, cash flows, dividends, financing plans, business strategies, operating efficiencies or synergies, budgets, capital and other expenditures, competitive positions, growth opportunities for existing or proposed products or services, plans and objectives of management, demand for new pharmaceutical products, market trends in the pharmaceutical business, inflation and various economic and business trends. Such forward-looking statements are subject to numerous risks and uncertainties, including risks that product candidates may fail in the clinic or may not be successfully marketed, the company may lack financial resources to complete development of product candidates, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. As a result of these and other risks and uncertainties, actual results may differ materially from those described in this press release.

SOURCE: Insmed Incorporated
COPYRIGHT 2001 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jul 10, 2001
Previous Article:HIV-AIDS Industry Report Features Aethlon Medical.
Next Article:Medis Technologies Successfully Demonstrates Direct Ethanol Fuel Cell.

Related Articles
PolyMedica Added to the Russell 2000 & Russell 3000 Indices.
Noven Pharmaceuticals Added to Russell Equity Indexes.
Matrix Pharmaceutical, Inc. Added to Russell 2000 Index.
Russell's 21 U.S. Equity Indexes Due for Annual Adjustment; Rebalancing Process Keeps Stock Benchmarks Tuned to Market Realities.
Russell Indexes: 2nd Quarter Preliminary Report -- Through June 27; Spring Surprise: 2nd Quarter Turns Positive for all 21 Indexes.
Russell Posts Final Company Membership for Stock Indexes 527 Additions to Broad Market Benchmark Include Only 130 IPOs; Median Market Cap Dips 7.5%...
Bruker Daltonics Added to the Russell 2000 Index.
Curis Added to the Russell 2000 and 3000 Indexes.
Merix Corporation Added to Russell 2000 Index.
SciClone Selected for Russell 3000 Index.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters